Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
NCT04569942 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2026-03-17
Summary
This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and early vasopressor regimen or a larger initial IV fluid volume with later introduction of vasopressors if required. Clinical care including the type of resuscitation fluid and vasopressor agent, will otherwise be in accordance with accepted standard care and according to clinician discretion. The study intervention will be delivered for at least 6 hours and up to 24 hours post-randomisation. Participants will be followed for up to 12 months and outcomes analysed on an intention-to-treat basis.
Conditions
- Shock, Septic
Interventions
- DRUG
-
Vasopressor
Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
- OTHER
-
Fluids
An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
Sponsors & Collaborators
-
Australian and New Zealand Intensive Care Research Centre
lead OTHER
Principal Investigators
-
Sandra Peake, MBBS · Monash University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-26
- Primary Completion
- 2026-02-01
- Completion
- 2026-11-03
Countries
- Australia
- Ireland
- New Zealand
Study Locations
More Related Trials
-
Fluid Intolerance Signals as Safety Limits to Prevent Fluid-induced Harm During Septic Shock Resuscitation
NCT06568744 ·Status: RECRUITING ·Phase: NA
-
Angiotensin in Septic Kidney Injury Trial
NCT00711789 ·Status: UNKNOWN ·Phase: PHASE2
-
Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis
NCT04280497 ·Status: RECRUITING ·Phase: NA
-
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
NCT01453270 ·Status: COMPLETED ·Phase: NA
-
Microcirculatory Oxygen Uptake in Sepsis
NCT02430142 ·Status: COMPLETED
-
Acetated Ringer's Solution Versus Saline in Patients With Septic Shock
NCT04507672 ·Status: UNKNOWN ·Phase: NA
-
Preemptive Resuscitation for Eradication of Septic Shock
NCT01449721 ·Status: COMPLETED ·Phase: NA
-
Individualised Blood Pressure Targets Versus Standard Care Among Critically Ill Patients With Shock
NCT05850962 ·Status: RECRUITING ·Phase: NA
-
Resuscitation Strategies in Septic Shock
NCT02150512 ·Status: UNKNOWN ·Phase: NA
-
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock
NCT01448109 ·Status: COMPLETED ·Phase: PHASE4
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
NCT04855786 ·Status: RECRUITING ·Phase: NA
-
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
NCT02079402 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock
NCT05094856 ·Status: COMPLETED
-
Sevoflurane in COVID-19 ARDS (SevCov)
NCT04355962 ·Status: COMPLETED ·Phase: PHASE3
-
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
NCT03434028 ·Status: COMPLETED ·Phase: PHASE3
-
Days Alive and Out of Hospital for Patients With Sepsis
NCT04567433 ·Status: COMPLETED
-
Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2
NCT06062303 ·Status: RECRUITING ·Phase: NA
-
Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock
NCT04948372 ·Status: COMPLETED ·Phase: NA
-
Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial
NCT00975793 ·Status: UNKNOWN ·Phase: PHASE3
-
Assessment of Fluid Responsiveness in Septic Shock Patients, Can End-tidal co2 Measurement Help?
NCT05557461 ·Status: UNKNOWN
-
The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
NCT06234592 ·Status: RECRUITING ·Phase: NA
-
Microcirculatory Guided Goal Directed Fluid Therapy in Septic Shock; a Feasibility Study
NCT03898674 ·Status: UNKNOWN ·Phase: NA
-
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
NCT03333278 ·Status: COMPLETED ·Phase: PHASE2
-
Fluid Resuscitation in Early Septic Shock
NCT00819416 ·Status: COMPLETED ·Phase: PHASE2
-
Protocolized Reduction of Non-resuscitation Fluids vs Usual Care in Septic Shock Feasibility Trial
NCT05249088 ·Status: COMPLETED ·Phase: NA